A.C. Correia

A.C. Correia

Auto-generated profile, based on publicly available information

A.C. Correia

University of Porto, UCIBIO, REQUIMTE, MEDTECH, Laboratory of Pharmaceutical Technology, Department, of Drug Sciences, Faculty of Pharmacy, Porto, Portugal; University of Porto, Associate Laboratory i4HB Institute for Health and Bioeconomy, Faculty of Pharmacy, Porto, Portugal

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2023 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
ACA.C. Correia
A.C. Correia
João Nuno MoreiraJoão Nuno Moreira
João Nuno Moreira
José Manuel Sousa LoboJosé Manuel Sousa Lobo
José Manuel Sousa Lobo
Ana Catarina SousaAna Catarina Sousa
Ana Catarina Sousa
The nose-to-brain route has been widely investigated to improve drug targeting to the central nervous system (CNS), where lipid nanoparticles (solid lipid nanoparticles - SLN and nanostructured lipid carriers - NLC) seem promising, although they should meet specific criteria of particle size (PS) < 200 nm, polydispersity index (PDI) < 0.3, zeta potential (ZP) ~|20| mV and encapsulation efficiency (EE) > 80%. To optimize SLN and NLC formulations, design of experiment (DoE) has been recommended as a quality by design (QbD) tool. This review presents recently published work on the optimization of SLN and NLC formulations for nose-to-brain drug delivery. The impact of different factors (or independent variables) on responses (or dependent variables) is critically analyzed. Different DoE have been used to optimize SLN and NLC formulations for nose-brain drug delivery, and the independent variables lipid and surfactant concentration and sonication time had the greatest impact on the dependent variables PS, EE and PDI. Exploring different DoE approaches is important to gain a deeper understanding of the factors that affect successful optimization of SLN and NLC and to facilitate future work improving machine learning techniques.

13 September 2025 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
ACA.C. Correia
A.C. Correia
GFGoncalo Farias
Goncalo Farias
LNLaura Nižić Nodilo
Laura Nižić Nodilo
DZD. Zadravec
D. Zadravec
LKL. Kalogjera
L. Kalogjera
Ana Catarina SousaAna Catarina Sousa
Ana Catarina Sousa
This study aimed to optimise key parameters for maximising olfactory deposition (OD) of a valproic acid (VPA)-loaded nanostructured lipid carriers (NLC) formulation, with particular focus on nasal device selection. Three nasal devices (unidose liquid nasal spray system - UDSl, VP7 pump equipped with a nose-to-brain actuator - VP7N2B, and Preloaded) were tested using two distinct 3D-printed nasal casts and varying administration positions. Among the tested devices, the Preloaded exhibited a narrow spray pattern with consistent delivery, achieving over 50 % OD. This makes it the most promising for nose-to-brain transport, surpassing OD values typically reported in the literature for both powder and liquid formulations, which rarely reach 50 %. Maximising OD required positioning the Preloaded device at a high angle to the horizontal plane (53°), a low angle to the vertical plane (5°), and a deeper insertion depth (ID) (15 mm). While the Preloaded device showed consistent OD across both models, greater variability was observed with UDSl and VP7N2B, likely due to anatomical differences between the nasal casts. These findings highlight the crucial role of nasal device design, spray characteristics, user-independent administration, and positioning in optimising OD. Although this work does not establish a universal in vitro testing method, it lays important groundwork and introduces experimental strategies that could guide future optimisation of NLC-based nasal drug delivery systems.